Cazenovia, NY – NCODA, Inc. is pleased to announce its collaboration with Evofem Biosciences to positively impact the quality of life for female patients undergoing treatment, those recovering from cancer, and survivors by raising awareness about the importance and availability of a new non-hormonal birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate).
Because many cancer treatment protocols require female patients of reproductive age to use birth control while undergoing treatment, NCODA and Evofem will work together to develop and share resources and educational information for the medically-integrated oncology pharmacy team to help support their female cancer patients in deciding which contraceptive option best meets each woman’s unique, individual needs.
NCODA plans to develop a Positive Quality Intervention (PQI) in connection with Phexxi. Part of the NCODA Quality Standards, PQIs are designed to operationalize and standardize practices to achieve positive outcomes for patients. The resource will educate oncologists and other members of the medically-integrated oncology pharmacy team who are involved in the care of oncology patients who may be prescribed Phexxi.
“Paramount to our mission is supporting the coordination and continuity of care while positively impacting clinical outcomes and quality of life for cancer patients,” said Michael J. Reff, NCODA Founder & Executive Director.
Phexxi is the first and only FDA-approved, non-hormonal contraceptive vaginal gel. It was approved in May 2020 and is now available in the U.S. by prescription. Phexxi works to maintain vaginal pH, which reduces sperm mobility, lowering the chance of sperm reaching the egg. It is the first hormone-free prescription contraceptive created for women in decades.
“Women who have or who have been previously treated for hormone-sensitive cancers should not use hormonal birth control because it may stimulate the growth of tumor cells,” said Gury Doshi, MD, Texas Oncology. “Non-hormonal birth control is the best option for these women, and it is important that each woman and her medical team evaluate and determine which of the two available hormone-free prescription contraceptives, a surgically implanted device or an on-demand vaginal pH modulator gel, is best for her.”
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). For more information, please visit www.evofem.com.
NCODA, Inc. is a 501(c)(3) organization. Our Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. For more information about NCODA’s Executive Council and general updates, visit www.ncoda.org.